The Change in Fibrinogen is Associated with Outcome in Patients with Acute Ischemic Stroke Treated with Endovascular Thrombectomy

被引:4
作者
Wang, Changyi [1 ,2 ,3 ]
Cui, Ting [1 ]
Li, Shucheng [1 ]
Wang, Tiantian [3 ]
Cui, Jingyu [1 ]
Zhong, Luyao [1 ]
Jiang, Shuai [1 ]
Zhu, Qiange [4 ]
Chen, Mingxi [1 ]
Yang, Yuan [1 ]
Wang, Anmo [1 ]
Zhang, Xuening [1 ]
Shang, Wenzuo [1 ]
Hao, Zilong [1 ]
Wu, Bo [1 ]
机构
[1] Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, Dept Neurol, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Key Lab Rehabil Med Sichuan Prov, Chengdu, Sichuan, Peoples R China
[4] Shaanxi Prov Peoples Hosp, Dept Neurol 2, Xian, Shaanxi, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
Ischemic stroke; Endovascular thrombectomy; Outcome; Fibrinogen; DEGRADATION COAGULOPATHY; INTRAVENOUS THROMBOLYSIS; PARENCHYMAL HEMATOMAS; RISK-FACTOR; RECANALIZATION; THERAPY; HYPERFIBRINOGENEMIA; INFLAMMATION; METAANALYSIS; ACTIVATION;
D O I
10.1007/s12028-023-01768-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BackgroundFibrinogen has been identified as a modulator of the coagulation and inflammatory process. There is uncertainty about the relationship between the dynamic profile of fibrinogen levels and its impact on clinical outcomes in patients with acute ischemic stroke treated with endovascular thrombectomy.MethodsWe consecutively enrolled patients with acute ischemic stroke who underwent endovascular thrombectomy. Fibrinogen was measured on admission and during hospitalization. The change in fibrinogen (Delta fibrinogen) was calculated as the highest follow-up fibrinogen minus admission fibrinogen, with a positive Delta fibrinogen indicating an increase in fibrinogen level. Functional outcome was assessed by the modified Rankin Scale at 3 months. Poor outcome was defined as modified Rankin Scale > 2.ResultsA total of 346 patients were included (mean age 67.4 +/- 13.6 years, 52.31% men). The median fibrinogen on admission was 2.77 g/L (interquartile range 2.30-3.39 g/L). The median Delta fibrinogen was 1.38 g/L (interquartile range 0.27-2.79 g/L). Hyperfibrinogenemia (> 4.5 g/L) on admission was associated with an increased risk of poor outcome [odds ratio (OR) 5.93, 95% confidence interval (CI) 1.44-24.41, p = 0.014]. There was a possible U-shaped association of Delta fibrinogen with outcomes, with an inflection point of - 0.43 g/L (p = 0.04). When Delta fibrinogen was < - 0.43 g/L, a higher decrease in fibrinogen (lower Delta fibrinogen value) was associated with a higher risk of poor outcome (OR 0.22, 95% CI 0.02-2.48, p = 0.219). When Delta fibrinogen was > - 0.43 g/L, the risk of poor outcome increased with increasing fibrinogen (OR 1.27, 95% CI 1.04-1.54, p = 0.016).ConclusionsIn patients with endovascular thrombectomy, hyperfibrinogenemia on admission was associated with poor functional outcomes at 3 months, whereas Delta fibrinogen was associated with poor 3-month outcomes in a possible U-shaped manner.
引用
收藏
页码:506 / 514
页数:9
相关论文
共 45 条
[1]   CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].
ADAMS, HP ;
BENDIXEN, BH ;
KAPPELLE, LJ ;
BILLER, J ;
LOVE, BB ;
GORDON, DL ;
MARSH, EE ;
KASE, CS ;
WOLF, PA ;
BABIKIAN, VL ;
LICATAGEHR, EE ;
ALLEN, N ;
BRASS, LM ;
FAYAD, PB ;
PAVALKIS, FJ ;
WEINBERGER, JM ;
TUHRIM, S ;
RUDOLPH, SH ;
HOROWITZ, DR ;
BITTON, A ;
MOHR, JP ;
SACCO, RL ;
CLAVIJO, M ;
ROSENBAUM, DM ;
SPARR, SA ;
KATZ, P ;
KLONOWSKI, E ;
CULEBRAS, A ;
CAREY, G ;
MARTIR, NI ;
FICARRA, C ;
HOGAN, EL ;
CARTER, T ;
GURECKI, P ;
MUNTZ, BK ;
RAMIREZLASSEPAS, M ;
TULLOCH, JW ;
QUINONES, MR ;
MENDEZ, M ;
ZHANG, SM ;
ALA, T ;
JOHNSTON, KC ;
ANDERSON, DC ;
TARREL, RM ;
NANCE, MA ;
BUDLIE, SR ;
DIERICH, M ;
HELGASON, CM ;
HIER, DB ;
SHAPIRO, RA .
STROKE, 1993, 24 (01) :35-41
[2]   Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: Lessons from multiple sclerosis [J].
Adams, R. A. ;
Schachtrup, C. ;
Davalos, D. ;
Tsigelny, I. ;
Akassoglou, K. .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (27) :2925-2936
[3]  
Adams RA, 2004, MOL INTERV, V4, P163
[4]  
[Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105
[5]   Inflammation and Stroke: An Overview [J].
Anrather, Josef ;
Iadecola, Costantino .
NEUROTHERAPEUTICS, 2016, 13 (04) :661-670
[6]   Protecting the ischaemic penumbra as an adjunct to thrombectomy for acute stroke [J].
Baron, Jean-Claude .
NATURE REVIEWS NEUROLOGY, 2018, 14 (06) :325-337
[7]   Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and infl ammation [J].
Chamorro, Angel ;
Dirnagl, Ulrich ;
Urra, Xabier ;
Planas, Anna M. .
LANCET NEUROLOGY, 2016, 15 (08) :869-881
[8]   Fibrinogen as a key regulator of inflammation in disease [J].
Davalos, Dimitrios ;
Akassoglou, Katerina .
SEMINARS IN IMMUNOPATHOLOGY, 2012, 34 (01) :43-62
[9]   Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke [J].
del Zoppo, Gregory J. ;
Levy, David E. ;
Wasiewski, Warren W. ;
Pancioli, Arthur M. ;
Demchuk, Andrew M. ;
Trammel, James ;
Demaerschalk, Bart M. ;
Kaste, Markku ;
Albers, Gregory W. ;
Ringelstein, Eric B. .
STROKE, 2009, 40 (05) :1687-1691
[10]   Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke [J].
Di Napoli, M ;
Papa, F ;
Bocola, V .
STROKE, 2001, 32 (01) :133-138